Royston, UK (22nd November 2011) – Microfluidics expert, Dolomite, is delighted to
announce its collaboration with Clearbridge BioMedics in the development of a novel
instrument capable of detecting and isolating Circulating Tumour Cells (CTCs) from
small quantities of whole, unprocessed blood.
The innovative ClearCell™ System can isolate, enumerate and most importantly retrieve
wholly intact and viable CTCs from patient whole blood. Benefiting a broad range of
application areas including molecule analysis, cancer diagnostics and cancer treatment
decisions, this revolutionary instrument also paves the way for personalised cancer
medication for patients.
Speaking of this success, Andrew Lovatt, the CEO of Dolomite, says, “We are excited to
be working with an innovative company like Clearbridge BioMedics. The collaboration is
an excellent example of how Dolomite is able to help start-up companies productize
science. By combining the cutting edge scientific research of Clearbridge BioMedics and
National University of Singapore with the proven track record in product development of
Dolomite, both companies have leveraged their expertise to gain early traction in the novel field of automated capture of viable CTCs. We are looking forward to extending our partnership beyond research tools and into the clinical diagnostic domain."
“We see microfluidics playing an increasing key role in many Companion Diagnostics
and In-Vitro Diagnostics devices. Dolomite has demonstrated that they are indeed a
leader in this field, and we look forward to developing our future platform devices and
systems together“, commented Johnson Chen, Managing Director of Clearbridge
For further information on Dolomite’s instrument development solutions as well as the
complete portfolio of microfluidic products including chips, connectors/ interconnects,
pumps, valves and custom devices please visit www.dolomite-microfluidics.com.
The Dolomite Centre Limited
Established in 2005 as the world’s first Microfluidic Application Centre, Dolomite focused on working with
customers to turn their concepts for microfluidic applications into reality. Today, Dolomite is the world leader
in solving microfluidic problems. With offices in the UK and US and distributors throughout the rest of the
world, its clients range from universities developing leading-edge analytical equipment, to manufacturers of
chemical, life sciences and clinical diagnostics systems.
Dolomite is pioneering the use of microfluidic devices for small-scale fluid control and analysis, enabling
manufacturers to develop more compact, cost-effective and powerful instruments. By combining specialist
glass, quartz and ceramic technologies with knowledge of high performance microfluidics, Dolomite is able to
provide solutions for a broad range of application areas including environmental monitoring, clinical
diagnostics, food and beverage, nuclear, agriculture, petrochemical, cosmetics, pharmaceuticals and
chemicals. Furthermore Dolomite's in-house micro-fabrication facilities that include clean rooms and precision
glass processing facilities allow to prototype and test all solutions rapidly which ensures a faster development
cycle and reduces the time to market.
For more information please visit www.dolomite-microfluidics.com.
Clearbridge BioMedics is a spin-off from the National University of Singapore (NUS), and an incubatee of
Clearbridge Accelerator, a Singapore Government backed high-technology incubator. Leveraging on a microfluidic biochip invention, its ClearCell™ System comprises patent-pending microfluidic CTChips®, which
are able to effectively detect and isolate wholly-intact CTCs (Circulating Tumour Cells) from small quantities of
whole patient blood samples.
Headquartered in Singapore, Clearbridge BioMedics currently has customers spanning Asia, Europe and North
For more information on Clearbridge BioMedics’ ClearCell™ System and CTChip®, please visit